These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34631561)

  • 21. Ascites Increases Expression/Function of Multidrug Resistance Proteins in Ovarian Cancer Cells.
    Mo L; Pospichalova V; Huang Z; Murphy SK; Payne S; Wang F; Kennedy M; Cianciolo GJ; Bryja V; Pizzo SV; Bachelder RE
    PLoS One; 2015; 10(7):e0131579. PubMed ID: 26148191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and biological evaluation of pentacyclic strychnos alkaloids as selective modulators of the ABCC10 (MRP7) efflux pump.
    Teijaro CN; Munagala S; Zhao S; Sirasani G; Kokkonda P; Malofeeva EV; Hopper-Borge E; Andrade RB
    J Med Chem; 2014 Dec; 57(24):10383-90. PubMed ID: 25419978
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic strategies to overcome taxane resistance in cancer.
    Das T; Anand U; Pandey SK; Ashby CR; Assaraf YG; Chen ZS; Dey A
    Drug Resist Updat; 2021 Mar; 55():100754. PubMed ID: 33691261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10(-/-) mice.
    Hopper-Borge EA; Churchill T; Paulose C; Nicolas E; Jacobs JD; Ngo O; Kuang Y; Grinberg A; Westphal H; Chen ZS; Klein-Szanto AJ; Belinsky MG; Kruh GD
    Cancer Res; 2011 May; 71(10):3649-57. PubMed ID: 21576088
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
    Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
    Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MiR-181a upregulation is associated with epithelial-to-mesenchymal transition (EMT) and multidrug resistance (MDR) of ovarian cancer cells.
    Li L; Xu QH; Dong YH; Li GX; Yang L; Wang LW; Li HY
    Eur Rev Med Pharmacol Sci; 2016 May; 20(10):2004-10. PubMed ID: 27249598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10).
    Chen ZS; Hopper-Borge E; Belinsky MG; Shchaveleva I; Kotova E; Kruh GD
    Mol Pharmacol; 2003 Feb; 63(2):351-8. PubMed ID: 12527806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function.
    Dai CL; Liang YJ; Chen LM; Zhang X; Deng WJ; Su XD; Shi Z; Wu CP; Ashby CR; Akiyama S; Ambudkar SV; Chen ZS; Fu LW
    Biochem Pharmacol; 2009 Aug; 78(4):355-64. PubMed ID: 19410561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance.
    Zhang H; Kathawala RJ; Wang YJ; Zhang YK; Patel A; Shukla S; Robey RW; Talele TT; Ashby CR; Ambudkar SV; Bates SE; Fu LW; Chen ZS
    Int J Biochem Cell Biol; 2014 Jun; 51():111-9. PubMed ID: 24726739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
    Sun YL; Kathawala RJ; Singh S; Zheng K; Talele TT; Jiang WQ; Chen ZS
    Anticancer Drugs; 2012 Sep; 23(8):865-73. PubMed ID: 22614107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors.
    Zhang H; Patel A; Wang YJ; Zhang YK; Kathawala RJ; Qiu LH; Patel BA; Huang LH; Shukla S; Yang DH; Ambudkar SV; Fu LW; Chen ZS
    Mol Cancer Ther; 2017 Jun; 16(6):1021-1030. PubMed ID: 28265007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs.
    Kathawala RJ; Wang YJ; Ashby CR; Chen ZS
    Chin J Cancer; 2014 May; 33(5):223-30. PubMed ID: 24103790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform.
    Zhang Y; Sriraman SK; Kenny HA; Luther E; Torchilin V; Lengyel E
    Mol Cancer Ther; 2016 Oct; 15(10):2282-2293. PubMed ID: 27466355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanisms of tetrandrine and 5-bromotetrandrine in reversing multidrug resistance may relate to down-regulation of multidrug resistance associated protein 7 expression.
    Cheng J; Dai JY; Chen BA; Cai XH; Wang S; Gao F
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):558-63. PubMed ID: 22739155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
    Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
    J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of an etoposide-resistant human ovarian cancer cell line.
    Kubota N; Nishio K; Takeda Y; Ohmori T; Funayama Y; Ogasawara H; Ohira T; Kunikane H; Terashima Y; Saijo N
    Cancer Chemother Pharmacol; 1994; 34(3):183-90. PubMed ID: 7911742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Marine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells.
    Abraham I; Jain S; Wu CP; Khanfar MA; Kuang Y; Dai CL; Shi Z; Chen X; Fu L; Ambudkar SV; El Sayed K; Chen ZS
    Biochem Pharmacol; 2010 Nov; 80(10):1497-506. PubMed ID: 20696137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds.
    Kars MD; Iseri OD; Gündüz U; Ural AU; Arpaci F; Molnár J
    Anticancer Res; 2006; 26(6B):4559-68. PubMed ID: 17201178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.
    Liu S; Sun J; Cai B; Xi X; Yang L; Zhang Z; Feng Y; Sun Y
    Tumour Biol; 2016 Jul; 37(7):9671-80. PubMed ID: 26801672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells.
    Zhang W; Fan YF; Cai CY; Wang JQ; Teng QX; Lei ZN; Zeng L; Gupta P; Chen ZS
    Front Pharmacol; 2018; 9():1097. PubMed ID: 30356705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.